- Report
- March 2021
- 268 Pages
Global
From €2365EUR$2,598USD£2,009GBP
€3379EUR$3,712USD£2,870GBP
- Book
- April 2022
- 288 Pages
- Book
- August 2019
- 768 Pages
- Book
- December 2011
- 368 Pages
- Book
- February 2011
- 366 Pages
- Book
- May 2014
- 224 Pages
- Book
- October 2012
- 524 Pages
€2785EUR$3,278USD£2,448GBP
- Book
- March 2020
- 500 Pages

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that affects the airways and makes it difficult to breathe. It is caused by long-term exposure to irritants such as cigarette smoke, air pollution, and chemical fumes. Symptoms of COPD include shortness of breath, wheezing, chest tightness, and coughing. COPD is a major cause of disability and death worldwide.
The COPD market is a rapidly growing segment of the global healthcare industry. It is estimated that COPD affects more than 300 million people worldwide, and the number is expected to increase in the coming years. The market is driven by the increasing prevalence of COPD, the development of new treatments, and the rising demand for better diagnosis and management of the disease.
The COPD market is highly competitive, with many companies offering a range of products and services. Some of the major players in the market include GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, and Merck. These companies are involved in the development of new treatments, diagnostic tools, and other products to improve the quality of life of COPD patients. Show Less Read more